Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:56:00 EDT Fri 17 Jul 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:RYTM - RHYTHM PHARMACEUTICALS INC - https://ir.rhythmtx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RYTM - Q0.1105.00·108.470.1106.60+0.510.5773.381,77210,604104.92  108.40  104.59122.20  74.5116:10:05Jul 0815 min RT 2¢

Recent Trades - Last 10 of 10604
Time ETExPriceChangeVolume
16:10:05Q106.600.511
16:10:05Q106.600.511
16:10:05Q106.600.511
16:10:05Q106.600.511
16:06:15Q105.01-1.081
16:04:57Q106.600.511
16:04:57Q106.600.511
16:04:55Q106.600.511
16:04:50Q106.600.511
16:04:41Q106.600.511

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-08 17:07U:RYTMNews ReleaseRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
2026-06-15 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
2026-06-13 08:01U:RYTMNews ReleaseRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
2026-06-12 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
2026-05-29 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
2026-05-28 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
2026-05-26 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
2026-05-12 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
2026-05-06 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
2026-05-05 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
2026-05-04 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
2026-05-01 06:55U:RYTMNews ReleaseRhythm Pharmaceuticals Announces IMCIVREE(TM) (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
2026-04-09 08:00U:RYTMNews ReleaseRhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
2026-04-03 09:00U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Changes to Board of Directors
2026-03-26 09:02U:RYTMNews ReleaseRhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE(TM) (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
2026-03-20 12:58U:RYTMNews ReleasePANTHERx(TM) Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE(TM) (setmelanotide)
2026-03-19 18:30U:RYTMNews ReleaseRhythm Pharmaceuticals Announces FDA Approval of IMCIVREE(TM) (setmelanotide) for Patients with Acquired Hypothalamic Obesity
2026-03-16 16:01U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
2026-03-01 12:30U:RYTMNews ReleaseRhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
2026-02-26 07:00U:RYTMNews ReleaseRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update